Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-105051
Filing Date
2025-08-07
Accepted
2025-08-07 16:16:58
Documents
55
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q kura-20250630.htm   iXBRL 10-Q 2289407
2 EX-10.1 kura-ex10_1.htm EX-10.1 29244
3 EX-10.2 kura-ex10_2.htm EX-10.2 78217
4 EX-10.4 kura-ex10_4.htm EX-10.4 320846
5 EX-31.1 kura-ex31_1.htm EX-31.1 12017
6 EX-32.1 kura-ex32_1.htm EX-32.1 10122
7 GRAPHIC img154426860_0.jpg GRAPHIC 149489
8 GRAPHIC img154426860_1.jpg GRAPHIC 427497
  Complete submission text file 0000950170-25-105051.txt   8656760

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kura-20250630.xsd EX-101.SCH 873301
58 EXTRACTED XBRL INSTANCE DOCUMENT kura-20250630_htm.xml XML 1216387
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37620 | Film No.: 251194281
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)